Overview
- The cyclic ionizable lipid AMG1541 was identified by iterative in vivo screens of a custom library using luciferase reporters in mice.
- In a flu model, AMG1541 LNPs matched antibody responses of SM-102–based formulations at roughly one percent of the dose.
- Experiments showed stronger endosomal escape, greater delivery to antigen‑presenting cells, and preferential lymph‑node accumulation.
- Ester‑linked tails rendered the particles degradable and rapidly cleared, which researchers say could lessen side effects.
- The study, led by MIT’s Anderson lab and published November 7 in Nature Nanotechnology, reports reduced liver expression after intramuscular dosing and suggests the platform could cut costs if results translate to humans.